Expertise in
45
conditions

Dr. Sudhir R. Manda

Oncology
TMc Health Cancer Center-Wilmot, Medical Oncology, Hematology & Gynecologic Oncology
603 N Wilmot Rd # 151, 
Tucson, AZ 
Accepting New Patients
Offers Telehealth
Expertise in
45
conditions
TMc Health Cancer Center-Wilmot, Medical Oncology, Hematology & Gynecologic Oncology
603 N Wilmot Rd # 151, 
Tucson, AZ 

Overview

Sudhir Manda is an Oncologist practicing medicine in Tucson, Arizona.

Dr. Manda is highly rated in 45 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Familial Colorectal Cancer, Lynch Syndrome, and Multiple Myeloma.

He is actively involved in clinical research, co-authoring 9 peer reviewed articles and participating in 13 clinical trials. Dr. Manda is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in NH

Hospital Affiliations

St Joseph's Hospital
Tucson Medical Center
Benson Hospital

Languages Spoken

English
Hindi

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MercyCare
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VibrantRx
  • MEDICARE PDP
  • OTHER MEDICARE
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

TMc Health Cancer Center-Wilmot, Medical Oncology, Hematology & Gynecologic Oncology
603 N Wilmot Rd # 151, Tucson, AZ 85711

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)
A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Drug
Study Drugs: Selinexor, Rituximab, Gemcitabine, Dexamethasone, Cisplatin
Study Phase: Phase 2/Phase 3
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Enrollment Status: Active_not_recruiting
Publish Date: May 15, 2026
Intervention Type: Drug
Study Drugs: LOXO-305, Ibrutinib, Acalabrutinib, Zanubrutinib
Study Phase: Phase 3
An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6)
An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6)
Enrollment Status: Terminated
Publish Date: May 04, 2026
Intervention Type: Drug
Study Drugs: Ixazomib, Lenalidomide, Dexamethasone
Study Phase: Phase 4
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Enrollment Status: Active_not_recruiting
Publish Date: April 24, 2026
Intervention Type: Drug
Study Drugs: Pirtobrutinib, Idelalisib, Bendamustine, Rituximab
Study Phase: Phase 3
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: January 21, 2026
Intervention Type: Drug, Device
Study Drugs: Gemcitabine, Nab-paclitaxel
Study Phase: Phase 3
Single-arm, Open Label, Phase II Study of MBG453 (Sabatolimab) Added to FDA Approved Hypomethylating Agents of Investigator's Choice (IV/SC/Oral) for Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria (US Multi-center) (STIMULUS MDS-US)
Single-arm, Open Label, Phase II Study of MBG453 (Sabatolimab) Added to FDA Approved Hypomethylating Agents of Investigator's Choice (IV/SC/Oral) for Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria (US Multi-center) (STIMULUS MDS-US)
Enrollment Status: Terminated
Publish Date: October 16, 2025
Intervention Type: Drug
Study Drugs: MBG453, Azacitidine, Decitabine, INQOVI
Study Phase: Phase 2
An Open-Label Phase Ib/II Study of Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
An Open-Label Phase Ib/II Study of Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: May 08, 2025
Intervention Type: Drug
Study Drug: Surufatinib+Tislelizumab
Study Phase: Phase 1/Phase 2
A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies
A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: February 10, 2025
Intervention Type: Drug
Study Drugs: SEA-TGT, Pembrolizumab
Study Phase: Phase 1
A Phase II Trial of Daratumumab, Lenalidomide and Dexamethasone (DRd) in Combination With Selinexor for Patients With Newly Diagnosed Multiple Myeloma
A Phase II Trial of Daratumumab, Lenalidomide and Dexamethasone (DRd) in Combination With Selinexor for Patients With Newly Diagnosed Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2025
Intervention Type: Drug
Study Drugs: Selinexor, Dexamethasone Oral, Daratumumab, Lenalidomide
Study Phase: Phase 2
PRESERVE 1: A Phase 3 Randomized, Double-blind Trial of Trilaciclib Versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
PRESERVE 1: A Phase 3 Randomized, Double-blind Trial of Trilaciclib Versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
Enrollment Status: Terminated
Publish Date: November 26, 2024
Intervention Type: Drug
Study Drug: Trilaciclib
Study Phase: Phase 3
View 9 Less Clinical Trials

9 Total Publications

Final Results of a Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma.
Final Results of a Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma.
Journal: EJHaem
Published: April 15, 2025
Similar Doctors
Expertise in
11
conditions
Expertise in
11
conditions
Referral may be required
Before you request

Banner-University Medical Center Tucson Campus

1625 North Campbell Avenue, 
Tucson, AZ 
 (5.2 miles away)
520-694-0111
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

I enjoy traveling, dancing and food. Dr. Shroff is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Cholangiocarcinoma (Bile Duct Cancer), Pancreatic Cancer, Gallbladder Cancer, Pancreaticoduodenectomy, and Pancreatectomy. Dr. Shroff is board certified in American Board Of Internal Medicine/Medical Oncology. Dr. Shroff is currently accepting new patients.

Expertise in
28
conditions
Expertise in
28
conditions
Referral may be required

TMc Health Cancer Center-Wilmot, Medical Oncology, Hematology & Gynecologic Oncology

603 N Wilmot Rd # 151, 
Tucson, AZ 
 (0.1 miles away)
520-420-2560
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Joseph Buscema is an Oncologist practicing medicine in Tucson, Arizona. Dr. Buscema is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Ovarian Cancer, Endometrial Cancer, Malignant Mixed Mullerian Tumor, and Testicular Yolk Sac Tumor. Dr. Buscema is currently accepting new patients.

Expertise in
25
conditions
Expertise in
25
conditions
Referral may be required
Before you request

Banner University Cancer Center

3838 N Campbell Ave, Bldg 1, 
Tucson, AZ 
 (5.9 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Linda Garland is an Oncologist practicing medicine in Tucson, Arizona. Dr. Garland is highly rated in 25 conditions, according to our data. Her clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Pleuropulmonary Blastoma. Dr. Garland is board certified in American Board Of Internal Medicine/Medical Oncology. Dr. Garland is currently accepting new patients.

Frequently Asked Questions about Dr. Sudhir R. Manda

How do I make an appointment with Dr. Sudhir R. Manda?

You can book an appointment with Dr. Sudhir R. Manda by calling their office at 520-420-2560. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Sudhir R. Manda a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Sudhir R. Manda is classified as an Distinguished expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Sudhir R. Manda specialize in?

While Dr. Sudhir R. Manda is a Oncology, they have specific expertise in Colorectal Cancer, Familial Colorectal Cancer, and Lynch Syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Sudhir R. Manda participate in research or clinical trials?

Yes. Dr. Sudhir R. Manda has published 9 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Dr. Sudhir R. Manda's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Sudhir R. Manda accept my insurance?

Dr. Sudhir R. Manda accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 520-420-2560 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Manda's expertise for a condition
ConditionClose
    View All 40 Advanced Conditions
    View All 85 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile